Structure-based drug design identifies novel LPA3 antagonists
James I Fells1, Ryoko Tsukahara, Jianxiong Liu
1Department of Chemistry and Computational Research on Materials Institute, The University of Memphis, Memphis, TN 38152, United States.
Bioorganic & Medicinal Chemistry
|October 6, 2009
Summary
Researchers identified novel antagonists for the lysophosphatidic acid receptor 3 (LPA3). These compounds, developed using structure-based drug design, show improved potency and selectivity for LPA3 antagonism.
Area of Science:
- Medicinal Chemistry
- Pharmacology
- Computational Chemistry
Background:
- Lysophosphatidic acid receptor 3 (LPA3) plays a role in various physiological processes.
- Developing selective LPA3 antagonists is a therapeutic goal.
- Previous efforts focused on dual LPA(2 and 3) antagonists.
Purpose of the Study:
- To identify novel and potent selective LPA3 antagonists.
- To optimize a dual LPA(2 and 3) antagonist pharmacophore.
- To utilize structure-based drug design for lead optimization.
Main Methods:
- Virtual screening was employed to identify initial hits.
- Structure-based drug design guided the prioritization of compounds.
- Experimental assays were used to determine antagonist efficacy (IC50 values).
Main Results:
- Compound 5 was identified as a weak selective LPA3 antagonist.
- A strategy using Compound 5 as a template rapidly identified 10 novel antagonists.
- Two novel compounds demonstrated significant inhibition of LPA3 receptor activation with IC50 values of 752 nM and 2992 nM.
Conclusions:
- The identified compounds represent improved LPA3 antagonists.
- The study refines the pharmacophore for LPA3 antagonists.
- This work advances the development of selective LPA3 receptor modulators.
Related Concept Videos
01:28Structure-Activity Relationships and Drug Design
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
01:26Drug Discovery: Overview
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
01:26Targets for Drug Action: Overview
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
01:21Antipsychotic Drugs: Typical and Atypical Agents
Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
01:25Drug-Receptor Interaction: Agonist
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
01:24Principles of Drug Action
Drugs are chemical substances that modify biological responses by interacting with macromolecular targets such as receptors, ion channels, transporters, and enzymes. Pharmacodynamics describes the course of action of drugs leading to the physiological effect at a specific site in the body.
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...